<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30114" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Thromboxane A2</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rucker</surname>
            <given-names>Dane</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dhamoon</surname>
            <given-names>Amit S.</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dane Rucker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amit Dhamoon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30114.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Thromboxane A2 (TxA2) is in the family of lipids known as eicosanoids, which are metabolites of arachidonic acid generated by the sequential action of&#x000a0;3 enzymes&#x02014;phospholipase A2, COX-1/COX-2 and TxA2&#x000a0;Synthase&#x000a0;(TXAS). TxA2&#x000a0;was originally described&#x000a0;as being released from platelets and is now known&#x000a0;to&#x000a0;be released&#x000a0;by various other cells, including macrophages, neutrophils,&#x000a0;and endothelial cells. Named after its role in thrombosis, TxA2 has&#x000a0;prothrombotic&#x000a0;properties, as it stimulates the activation of platelets&#x000a0;and platelet aggregation. TxA2 is also a known&#x000a0;vasoconstrictor&#x000a0;and gets activated during times of tissue injury and inflammation. While prostaglandin counterbalances its thrombotic and vasoconstrictor properties, prostacyclin (PGI2) has various physiological and pathological situations where this balance becomes dysregulated.<xref ref-type="bibr" rid="article-30114.r1">[1]</xref>&#x000a0;Increased activity of TxA2 may play a role in the pathogenesis of myocardial infarction, stroke, atherosclerosis, and bronchial asthma.<xref ref-type="bibr" rid="article-30114.r2">[2]</xref>&#x000a0;Increased action of TxA2 also has implications in pulmonary hypertension, kidney injury, hepatic injury, allergies, angiogenesis, and metastasis of cancer cells.<xref ref-type="bibr" rid="article-30114.r3">[3]</xref><xref ref-type="bibr" rid="article-30114.r4">[4]</xref><xref ref-type="bibr" rid="article-30114.r5">[5]</xref><xref ref-type="bibr" rid="article-30114.r6">[6]</xref><xref ref-type="bibr" rid="article-30114.r7">[7]</xref><xref ref-type="bibr" rid="article-30114.r8">[8]</xref></p>
      </sec>
      <sec id="article-30114.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>TxA2 is a potent platelet activator and vasoconstrictor that may have pathological consequences when activation is uncontrolled.</p>
      </sec>
      <sec id="article-30114.s3" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>TxA2 is involved in multiple biological processes via its cell surface receptor, termed the TP. The TP is a&#x000a0;G protein-coupled&#x000a0;receptor (GPCR) expressed in various tissues and cells, including platelets, vasculature (smooth muscle and endothelial cells), lungs, kidneys, heart, thymus, and spleen. Two highly related&#x000a0;isoforms&#x000a0;of the TP (alpha and beta) arise through differential&#x000a0;mRNA&#x000a0;splicing, a characteristic exclusive to the human receptor.<xref ref-type="bibr" rid="article-30114.r9">[9]</xref> In most tissues, both&#x000a0;isoforms are expressed; however, only the&#x000a0;TP-alpha form&#x000a0;is in platelets. The TP not only undergoes activation by&#x000a0;TxA2&#x000a0;but also&#x000a0;isoprostanes, which are free radical-catalyzed peroxidation products of arachidonic acid without the direct action of COX enzymes.</p>
      </sec>
      <sec id="article-30114.s4" sec-type="Development">
        <title>Development</title>
        <p>The production of TxA2 is via a sequential process that begins with arachidonic acid (AA). Arachidonic acid is a polyunsaturated fatty acid present in the phospholipid membrane of the body&#x02019;s cells. In the setting of inflammation, phospholipase A2 cleaves arachidonic acid from the cell&#x02019;s membrane and, through one&#x000a0;pathway,&#x000a0;is converted&#x000a0;to prostaglandin H2 (PGH2) via the action of the enzyme COX. There are&#x000a0;2 evolutionarily conserved COX&#x000a0;isoforms, including COX-1 and COX-2. COX-1&#x000a0;is constitutively expressed&#x000a0;in platelets, and COX-2 is an inducible form found only in a small fraction of circulating platelets under normal conditions. COX-2&#x000a0;is shown&#x000a0;to have increased expression in newly formed platelets and during times of inflammation and other provoked settings compared to normal conditions. PGH2 ultimately converts into the product TxA2 via the enzyme TXAS.<xref ref-type="bibr" rid="article-30114.r10">[10]</xref></p>
      </sec>
      <sec id="article-30114.s5" sec-type="Function">
        <title>Function</title>
        <p>TxA2 serves as a positive-feedback mediator during platelet activation.&#x000a0;Because of&#x000a0;its short half-life of about 30 seconds, TxA2 acts in an autocrine or paracrine matter to activate adjacent platelets, generate more TxA2, and amplify the action of other, more potent, platelet agonists. When TxA2 binds to TP, platelet activation leads to&#x000a0;platelet-shape change, activation of phospholipase A2, platelet degranulation of dense granules and alpha granules, and platelet aggregation. TxA2 also induces vasoconstriction of smooth muscle<bold>.</bold><xref ref-type="bibr" rid="article-30114.r11">[11]</xref></p>
      </sec>
      <sec id="article-30114.s6" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>When platelets circulate through vessels with intact endothelium, they remain inactivated. This inactivated state is supported by the release of prostacyclin (PGI2) from the intact endothelium and the absence of various activating factors. However, when a platelet encounters a break in the endothelium, it encounters molecules such as collagen, ADP, thrombin, and TxA2 that trigger its activation.<xref ref-type="bibr" rid="article-30114.r12">[12]</xref></p>
        <p>
<bold>Platelet Activation</bold>
</p>
        <p>The predominant activators of platelets are diffusible stimuli such as ADP, TxA2, and thrombin. They all work by initiating the aggregation of platelets into a growing thrombus through the action of various G protein-mediated signaling pathways. These pathways converge to induce platelet-shape change, degranulation, and integrin Glycoprotein (GP)&#x000a0;IIb/IIIa&#x000a0;mediated aggregation. Each stimulus uses a distinct mechanism, but ultimately, all of the mechanisms are involved in full platelet activation. TxA2 activates mainly Gq and G12/G13 via the TP. Gq family members of heterotrimeric G protein activate beta&#x000a0;isoforms&#x000a0;of phospholipase C (PLC) that hydrolyzes phosphatidylinositol phosphate (PIP) to&#x000a0;diacylglycerol&#x000a0;(DAG) and inositol&#x000a0;trisphosphate&#x000a0;(IP3), leading to protein kinase C (PKC) activation as well as intracellular Ca(2+) accumulation, respectively. G12/13 signaling of GPCRs has recently been shown to involve activation of&#x000a0;RhoGTPase&#x000a0;nucleotide exchange factors (RhoGEFs).<xref ref-type="bibr" rid="article-30114.r13">[13]</xref></p>
        <p>Because all mediators can, in turn, multiply the formation and release of thrombin, TxA2, and ADP,&#x000a0;their effects are amplified, and ultimately, all major G protein-mediated&#x000a0;signaling pathways are activated. This grouped activation inherently makes specific pathways challenging to isolate. However, research has proven that&#x000a0;an increase in the free cytosolic [Ca] and activation of PKC are necessary for platelet activation, and this is precisely what occurs when TxA2 activates the&#x000a0;Gq pathway.<xref ref-type="bibr" rid="article-30114.r14">[14]</xref>&#x000a0;</p>
        <p>
<bold>Platelet-Shape Change</bold>
</p>
        <p>A shape change is the platelets' initial response to activators such as TxA2. It is&#x000a0;an extremely&#x000a0;rapid process caused by a reorganization of the cytoskeleton. The mediation of platelet-shape change&#x000a0;is mostly by myosin light chain (MLC) phosphorylation.&#x000a0;MLC phosphorylation can be controlled&#x000a0;through a Ca2+/calmodulin-dependent regulation of MLC kinase, controlled by the activation of&#x000a0;Gq and&#x000a0;through a Rho/Rho-kinase-mediated regulation of myosin phosphatase, controlled by the activation of G12/G13.<xref ref-type="bibr" rid="article-30114.r15">[15]</xref>&#x000a0;During platelet-shape change,&#x000a0;new actin filaments are formed, leading to the formation of a submembranous actin filament network and the extension of filopodia. Also, the actomyosin-based contractile processes are stimulated, resulting in the centralization of dense and alpha granules. Finally, the circumferential microtubule coil&#x000a0;depolymerizes, which allows the platelet to change from a discoid to a spherical shape. The platelet shape change, induced&#x000a0;by agonist concentrations lower than those required for degranulation and aggregation,&#x000a0;is believed&#x000a0;to be a prerequisite for efficient secretion of granule contents and greatly facilitates the adhesion of platelets to each other and&#x000a0;components of the extracellular matrix.<xref ref-type="bibr" rid="article-30114.r16">[16]</xref><xref ref-type="bibr" rid="article-30114.r17">[17]</xref></p>
        <p>
<bold>Platelet Degranulation</bold>
</p>
        <p>A variety of mediators can induce platelet degranulation. TxA2 induces platelet degranulation via the Gq/PLC-beta pathway. Secretion from platelets is an important mechanism that amplifies platelet activation and results in the release of mediators that act on the vessel wall&#x000a0;and other blood cells. It occurs in 2&#x000a0;waves; the first&#x000a0;consists of&#x000a0;the release of dense core granules and alpha-granules, followed by lysosome release. Dense granules contain small molecules such as nucleotides (ADP, ATP) or serotonin, whereas alpha granules contain various proteins, including growth factors,&#x000a0;chemokines, adhesive molecules such as Von Willebrand Factor (vWF), and coagulation factors. The central role of the Gq/PLC-beta pathway in agonist-induced platelet granule secretion&#x000a0;is supported&#x000a0;by the finding that various platelet activators&#x000a0;failed to&#x000a0;induce secretion in platelets lacking&#x000a0;Galpha-q and&#x000a0;by the fact that&#x000a0;secretion in response to TxA2 is reduced in&#x000a0;PLC-beta&#x02013;deficient platelets.<xref ref-type="bibr" rid="article-30114.r18">[18]</xref></p>
        <p>
<bold>Platelet Aggregation</bold>
</p>
        <p>While the exact signaling mechanisms that link receptors of platelet activators to the cytoplasmic domains of GP IIb/IIIa&#x000a0;are incompletely understood, there is good evidence that activation of PLC-beta through&#x000a0;Gq, which results in the formation of IP3&#x000a0;and DAG, plays a role in mediating GP IIb/IIIa&#x000a0;activation. IP3-mediated increases in cytosolic-free Ca and activated PKC appear to&#x000a0;be necessary for activating the integrin GP IIb/IIIa.&#x000a0;This intracellular signaling pathway results in a conformational change of GP IIb/IIIa to an active form and is referred to as &#x0201c;inside-out&#x0201d; signaling. It results in fibrinogen/vWF-mediated platelet aggregation.<xref ref-type="bibr" rid="article-30114.r19">[19]</xref></p>
        <p>
<bold>Contraction</bold>
</p>
        <p>Since finding TxA2 to be a rabbit aorta-contracting substance, TxA2 has a potent contractile activity towards vascular smooth muscle cells.&#x000a0;In addition to&#x000a0;vascular smooth muscle, TxA2 causes contraction of bronchial smooth muscle, intestinal smooth, uterus, and urinary bladder muscles.<xref ref-type="bibr" rid="article-30114.r11">[11]</xref>&#x000a0;When TxA2 binds to its receptor, there is an influx of calcium ions, directly increasing the contraction of smooth muscle cells.<xref ref-type="bibr" rid="article-30114.r20">[20]</xref>&#x000a0;The vasoconstriction caused by TxA2 aids in platelet aggregation because platelets are close to each other, which leads to greater clot formation.</p>
      </sec>
      <sec id="article-30114.s7" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of TxA2 includes increased production in the setting of injury and inflammation. Increased production leads to increased TP activation, which increases platelet activation, aggregation, and vasoconstriction. These all result in thrombosis and, thus, decreased blood flow to various body parts.&#x000a0;Furthermore, pathological&#x000a0;states can disturb the physiologic redox state of cells, leading to increased ROS. Exposure of these ROS to membrane lipids can induce nonenzymatic peroxidation reactions, leading to the production of isoprostanes, which also activate the TP and increase rates of thrombosis.<xref ref-type="bibr" rid="article-30114.r21">[21]</xref></p>
      </sec>
      <sec id="article-30114.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Cardiovascular&#x000a0;Disease: The&#x000a0;biosynthesis of TxA2 and&#x000a0;isoprostanes&#x000a0;is elevated in numerous cardiovascular and inflammatory&#x000a0;diseases,&#x000a0;as&#x000a0;is the expression of&#x000a0;the receptor itself.</p>
        <p>
<bold>Myocardial Infarction</bold>
</p>
        <p>Myocardial infarction occurs when there is a complete occlusion of blood flow to an area&#x000a0;of the heart. Thrombus formation mediated by TxA2-induced platelet aggregation and vascular constriction sometimes causes myocardial infarction (as well as&#x000a0;infarctions of other organs).<xref ref-type="bibr" rid="article-30114.r10">[10]</xref></p>
        <p><bold>Atherosclerosis</bold>&#x000a0;</p>
        <p>Atherosclerosis is a chronic disease of the vasculature that&#x000a0;is influenced&#x000a0;by multiple factors involving a complex interplay between the blood and the arterial wall components. TxA2, isoprostanes, and PGI2 are known to&#x000a0;promote the initiation and progression of atherogenesis through control of platelet activation and leukocyte-endothelial cell interaction.<xref ref-type="bibr" rid="article-30114.r22">[22]</xref></p>
        <p>
<bold>Variant (Prinzmetal) Angina&#x000a0;</bold>
</p>
        <p>Studies have also&#x000a0;indicated&#x000a0;that increased TxA2 in circulating plasma&#x000a0;is closely correlated&#x000a0;with the hypersensitivity of coronary arteries to ergonovine maleate in patients with variant angina, suggesting a possible role of augmented TxA2 production in enhancing coronary vascular spasticity.<xref ref-type="bibr" rid="article-30114.r23">[23]</xref></p>
        <p>
<bold>Treatment in Cardiovascular Disease</bold>
</p>
        <p>Irreversible inhibition of COX-1-derived TxA2 with low-dose aspirin affords prophylaxis against both primary and secondary vascular thrombotic events, underscoring the central role of TxA2 as a platelet agonist in cardiovascular disease. However, COX-1 inhibitors have correlations with adverse effects such as GI toxicity and bleeding.<xref ref-type="bibr" rid="article-30114.r10">[10]</xref>&#x000a0;Furthermore, selective&#x000a0;COX-2 inhibitors cause cardiotoxicity, which may&#x000a0;be related&#x000a0;to the inhibition of PGI2 production while maintaining the production of TxA2 via COX-1; this makes TP and TXAS antagonists potential therapeutic targets for the treatment and prevention of CVD.</p>
        <p><bold>Lung</bold>&#x000a0;</p>
        <p>TxA2-induced contraction of bronchial smooth muscles may contribute to asthma, which has&#x000a0;been improved&#x000a0;by TP antagonists.<xref ref-type="bibr" rid="article-30114.r24">[24]</xref>&#x000a0;TxA2 is also involved in bronchial muscle hyperplasia and airway remodeling in asthma.<xref ref-type="bibr" rid="article-30114.r25">[25]</xref>&#x000a0; Studies have also shown that pulmonary hypertension associated with ischemia-reperfusion results in part from the pulmonary release of TxA2.<xref ref-type="bibr" rid="article-30114.r3">[3]</xref></p>
        <p><bold>Kidney</bold>&#x000a0;</p>
        <p>TxA2 is involved in nephritis and nephrotic syndrome of the kidney.<xref ref-type="bibr" rid="article-30114.r4">[4]</xref>&#x000a0;TP stimulation of mesangial cells causes cell contraction, promotes proliferation, changes cellular ion fluxes, and increases the&#x000a0;mRNA&#x000a0;levels of fibronectin, laminin, collagen, tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and&#x000a0;accelerates&#x000a0;transforming growth factor synthesis.<xref ref-type="bibr" rid="article-30114.r11">[11]</xref></p>
        <p><bold>Liver</bold>&#x000a0;</p>
        <p>Hepatic injury after hepatic stress results from several mechanisms, including inflammation and microcirculatory disturbance.&#x000a0;Levels of thromboxane have been shown&#x000a0;to&#x000a0;increase&#x000a0;in the systemic circulation after different&#x000a0;types of&#x000a0;hepatic stress such as endotoxemia, hepatic ischemia-reperfusion, hepatectomy, liver transplantation, hemorrhagic shock and resuscitation, hepatic cirrhosis, and alcoholic liver injury.&#x000a0;The production of thromboxane from the liver also becomes enhanced&#x000a0;under these stresses. Thromboxane induces hepatic damage through vasoconstriction, platelet aggregation, induction of leukocyte adhesion, up-regulation of proinflammatory cytokines, and release of other vasoconstrictors.<xref ref-type="bibr" rid="article-30114.r5">[5]</xref></p>
        <p>
<bold>Allergy and Inflammation</bold>
</p>
        <p>Research shows that TxA2 contributes to asthma, rhinitis, and atopic dermatitis pathogenesis. Allergic inflammation is the fundamental pathophysiology of allergic diseases and closely correlates with disease progression and exacerbation.<xref ref-type="bibr" rid="article-30114.r6">[6]</xref></p>
        <p><bold>Angiogenesis and Metastasis of Cancer Cells</bold>&#x000a0;</p>
        <p>TxA2 is implicated in modulating angiogenesis during tumor growth and chronic inflammation and is involved in angiotensin II-induced neovascularization.<xref ref-type="bibr" rid="article-30114.r7">[7]</xref>&#x000a0;Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) stimulate endothelial cell migration mediated by TxA2. Additionally, TxA2 is involved in the metastasis of cancer cells.<xref ref-type="bibr" rid="article-30114.r8">[8]</xref></p>
      </sec>
      <sec id="article-30114.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30114&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30114">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30114/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30114">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30114.s10">
        <title>References</title>
        <ref id="article-30114.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Rocca</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Koller</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Coffman</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Grosser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Role of prostacyclin in the cardiovascular response to thromboxane A2.</article-title>
            <source>Science</source>
            <year>2002</year>
            <month>Apr</month>
            <day>19</day>
            <volume>296</volume>
            <issue>5567</issue>
            <fpage>539</fpage>
            <page-range>539-41</page-range>
            <pub-id pub-id-type="pmid">11964481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Negishi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sugimoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ichikawa</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanisms of diverse actions of prostanoid receptors.</article-title>
            <source>Biochim Biophys Acta</source>
            <year>1995</year>
            <month>Oct</month>
            <day>26</day>
            <volume>1259</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <page-range>109-19</page-range>
            <pub-id pub-id-type="pmid">7492609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zamora</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Heffner</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Thromboxane contributes to pulmonary hypertension in ischemia-reperfusion lung injury.</article-title>
            <source>J Appl Physiol (1985)</source>
            <year>1993</year>
            <month>Jan</month>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>224</fpage>
            <page-range>224-9</page-range>
            <pub-id pub-id-type="pmid">8444695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spurney</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pisetsky</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Coffman</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Physiologic role for enhanced renal thromboxane production in murine lupus nephritis.</article-title>
            <source>Prostaglandins</source>
            <year>1991</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-28</page-range>
            <pub-id pub-id-type="pmid">1771236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yokoyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nimura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nagino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bland</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Chaudry</surname>
                <given-names>IH</given-names>
              </name>
            </person-group>
            <article-title>Role of thromboxane in producing hepatic injury during hepatic stress.</article-title>
            <source>Arch Surg</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>140</volume>
            <issue>8</issue>
            <fpage>801</fpage>
            <page-range>801-7</page-range>
            <pub-id pub-id-type="pmid">16103291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sugiura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Uehara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>XQ</given-names>
              </name>
              <name>
                <surname>Shirakawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hopkin</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Genetic variants of the receptors for thromboxane A2 and IL-4 in atopic dermatitis.</article-title>
            <source>Biochem Biophys Res Commun</source>
            <year>2002</year>
            <month>Apr</month>
            <day>05</day>
            <volume>292</volume>
            <issue>3</issue>
            <fpage>776</fpage>
            <page-range>776-80</page-range>
            <pub-id pub-id-type="pmid">11922633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Silvestre</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Waeckel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Corda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verbeuren</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vilaine</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Clergue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duriez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>BI</given-names>
              </name>
            </person-group>
            <article-title>Thromboxane A2/prostaglandin H2 receptor activation mediates angiotensin II-induced postischemic neovascularization.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>488</fpage>
            <page-range>488-93</page-range>
            <pub-id pub-id-type="pmid">16385086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lamberti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zacharek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Szekeres</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Honn</surname>
                <given-names>KV</given-names>
              </name>
            </person-group>
            <article-title>Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis.</article-title>
            <source>Biochem Biophys Res Commun</source>
            <year>2000</year>
            <month>Jan</month>
            <day>07</day>
            <volume>267</volume>
            <issue>1</issue>
            <fpage>245</fpage>
            <page-range>245-51</page-range>
            <pub-id pub-id-type="pmid">10623605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raychowdhury</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Yukawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>McGrail</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor.</article-title>
            <source>J Biol Chem</source>
            <year>1994</year>
            <month>Jul</month>
            <day>29</day>
            <volume>269</volume>
            <issue>30</issue>
            <fpage>19256</fpage>
            <page-range>19256-61</page-range>
            <pub-id pub-id-type="pmid">8034687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smyth</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Thromboxane and the thromboxane receptor in cardiovascular disease.</article-title>
            <source>Clin Lipidol</source>
            <year>2010</year>
            <month>Apr</month>
            <day>01</day>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-219</page-range>
            <pub-id pub-id-type="pmid">20543887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakahata</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology.</article-title>
            <source>Pharmacol Ther</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>118</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-35</page-range>
            <pub-id pub-id-type="pmid">18374420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassall</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Bruckdorfer</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin.</article-title>
            <source>Biochem J</source>
            <year>1983</year>
            <month>Oct</month>
            <day>15</day>
            <volume>216</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-9</page-range>
            <pub-id pub-id-type="pmid">6360159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Offermanns</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Activation of platelet function through G protein-coupled receptors.</article-title>
            <source>Circ Res</source>
            <year>2006</year>
            <month>Dec</month>
            <day>08</day>
            <volume>99</volume>
            <issue>12</issue>
            <fpage>1293</fpage>
            <page-range>1293-304</page-range>
            <pub-id pub-id-type="pmid">17158345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rink</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Tsien</surname>
                <given-names>RY</given-names>
              </name>
            </person-group>
            <article-title>Cytoplasmic free Ca2+ in human platelets: Ca2+ thresholds and Ca-independent activation for shape-change and secretion.</article-title>
            <source>FEBS Lett</source>
            <year>1982</year>
            <month>Nov</month>
            <day>01</day>
            <volume>148</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-6</page-range>
            <pub-id pub-id-type="pmid">6816632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Retzer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilde</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Maschberger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Essler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aepfelbacher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Siess</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets.</article-title>
            <source>Blood</source>
            <year>1999</year>
            <month>Sep</month>
            <day>01</day>
            <volume>94</volume>
            <issue>5</issue>
            <fpage>1665</fpage>
            <page-range>1665-72</page-range>
            <pub-id pub-id-type="pmid">10477691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartwig</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of actin rearrangements mediating platelet activation.</article-title>
            <source>J Cell Biol</source>
            <year>1992</year>
            <month>Sep</month>
            <volume>118</volume>
            <issue>6</issue>
            <fpage>1421</fpage>
            <page-range>1421-42</page-range>
            <pub-id pub-id-type="pmid">1325975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wurzinger</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Histophysiology of the circulating platelet.</article-title>
            <source>Adv Anat Embryol Cell Biol</source>
            <year>1990</year>
            <volume>120</volume>
            <fpage>1</fpage>
            <page-range>1-96</page-range>
            <pub-id pub-id-type="pmid">2264500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Draznin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eslin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Poncz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>The relative role of PLCbeta and PI3Kgamma in platelet activation.</article-title>
            <source>Blood</source>
            <year>2005</year>
            <month>Jul</month>
            <day>01</day>
            <volume>106</volume>
            <issue>1</issue>
            <fpage>110</fpage>
            <page-range>110-7</page-range>
            <pub-id pub-id-type="pmid">15705797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bennett</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Structure and function of the platelet integrin alphaIIbbeta3.</article-title>
            <source>J Clin Invest</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>115</volume>
            <issue>12</issue>
            <fpage>3363</fpage>
            <page-range>3363-9</page-range>
            <pub-id pub-id-type="pmid">16322781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Comerma-Steffensen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arcanjo</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Simonsen</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms Involved in Thromboxane A<sub>2</sub> -induced Vasoconstriction of Rat Intracavernous Small Penile Arteries.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>119 Suppl 3</volume>
            <fpage>86</fpage>
            <page-range>86-95</page-range>
            <pub-id pub-id-type="pmid">26708952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bauer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ripperger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frantz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Erg&#x000fc;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schwedhelm</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Benndorf</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation.</article-title>
            <source>Br J Pharmacol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>171</volume>
            <issue>13</issue>
            <fpage>3115</fpage>
            <page-range>3115-31</page-range>
            <pub-id pub-id-type="pmid">24646155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The combined role of atheroma, cholesterol, platelets, the endothelium and fibrin in heart attacks and strokes.</article-title>
            <source>Med Hypotheses</source>
            <year>1984</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>305</fpage>
            <page-range>305-22</page-range>
            <pub-id pub-id-type="pmid">6521675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuzuya</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kodama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mishima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Inui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Elevation of thromboxane B2 levels in patients with classic and variant angina Pectoris.</article-title>
            <source>Circulation</source>
            <year>1981</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>1107</fpage>
            <page-range>1107-15</page-range>
            <pub-id pub-id-type="pmid">7296786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Uhlig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ullrich</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Cytokine-induced bronchoconstriction in precision-cut lung slices is dependent upon cyclooxygenase-2 and thromboxane receptor activation.</article-title>
            <source>Am J Respir Cell Mol Biol</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-45</page-range>
            <pub-id pub-id-type="pmid">11159047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30114.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vignola</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mirabella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Costanzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Giorgi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gjomarkaj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bellia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bonsignore</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Airway remodeling in asthma.</article-title>
            <source>Chest</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>123</volume>
            <issue>3 Suppl</issue>
            <fpage>417S</fpage>
            <page-range>417S-22S</page-range>
            <pub-id pub-id-type="pmid">12629009</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
